Corcept Therapeutics opened lower at $72.23, compared with its previous close of $74.53. In the last trading session, the stock traded between $72.23 and $75.50. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Corcept Therapeutics is now worth
$ 326.84
Giving a profit of
$ 226.84 (226.84%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.83 (-1.11%)
Day High
$75.50
Day Low
$72.23
Day Open
$72.23
Prev Close
$74.53
Volume
6,53,375
1W Return
-6.89%
1M Return
-39.23%
3M Return
-34.09%
6M Return
43.95%
1Y Return
-6.72%
Market Cap ($ Mn)
8,066
PE Ratio
253.07
PB Ratio
17.41
PEG Ratio
70.96
ROE
15.20%
ROCE
6.62%
EPS (TTM)
$1.14
1 Week
-6.89%
1 Month
-39.23%
3 Months
-34.09%
6 Months
43.95%
9 Months
80.51%
Piper Sandler raises Corcept Therapeutics price target to $173
Piper Sandler reiterated Overweight rating on Corcept Therapeutics. Price target raised from $165 to $173. Analyst David Amsellem led the rating revision.
8 days agoCorcept Therapeutics Q3 revenue up 64% YoY to $340.5 million
Revenue rose 64% YoY to $340.5 million, driven by Korlym ($249.1 million) and Lithioli ($91.4 million). Net income increased to $126.8 million from $19.7 million in the prior-year quarter. Lithioli revenue grew 92% sequentially; management targets >$1 billion annual revenue for the drug. Cash and investments increased by $118 million during the quarter to reach $662 million. Full-year 2026 revenue guidance reiterated at $1.1 billion to $1.2 billion despite strong Q3 performance.
9 days agoADA/EASD recommend hypercortisolism screening in hard-to-treat diabetes
ADA and EASD recommend screening for hypercortisolism in adults with difficult-to-control type 2 diabetes. CATALYST trial showed mifepristone reduced HbA1c by 1.47% versus 0.15% for placebo. Hypercortisolism was identified in 24% of 1,057 patients screened with difficult-to-control diabetes. Report cites mifepristone as potentially beneficial for managing hyperglycemia in non-ACTH-dependent cases.
23 days agoEU CHMP recommends Corcept Lifyorli for platinum-resistant ovarian cancer
CHMP recommends EU approval for Corcept's Lifyorli combined with nab-paclitaxel. Indication covers platinum-resistant ovarian cancer treatment. EC final decision expected in fourth quarter of 2026. Pivotal ROSELLA trial showed improved survival vs monotherapy. Safety profile consistent with nab-paclitaxel alone.
1mo agoCorcept Therapeutics stock returns 33.86% annually over last decade
Corcept Therapeutics posted a 33.86% average annual return over the last 10 years. The stock outperformed the broader market by 20.4% on an annualized basis. Current market capitalization stands at $12.42 billion. A $1,000 investment from a decade ago is now worth $19,271.81.
1mo agoCorcept Therapeutics shares surge 22% after Q2 beat, guidance raise
Corcept Therapeutics delivered a robust Q2 performance with EPS of $0.36 and revenue of $256.1 million, significantly beating analyst estimates. Shares jumped nearly 22% after hours as the company highlighted strong oncology results from Lifyorli and raised full-year revenue guidance to $1.1-1.2 billion.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Corcept Therapeutics is now worth
$ 326.84
Giving a profit of
$ 226.84 (226.84%)
Note: Past profits do not guarantee future returns.
